Lo Minastrin Fe is a drug owned by Allergan Pharmaceuticals International Ltd. It is protected by 3 US drug patents filed in 2013. Out of these, 1 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 02, 2029. Details of Lo Minastrin Fe's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7704984 | Extended estrogen dosing contraceptive regimen |
Feb, 2029
(3 years from now) | Active |
| US6667050 | Chewable oral contraceptive |
Apr, 2019
(6 years ago) |
Expired
|
| US5552394 | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul, 2014
(10 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lo Minastrin Fe's patents.
Latest Legal Activities on Lo Minastrin Fe's Patents
Given below is the list of recent legal activities going on the following patents of Lo Minastrin Fe.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 09 Sep, 2021 | US7704984 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Oct, 2017 | US7704984 (Litigated) |
| File Marked Found | 20 Jan, 2016 | US6667050 (Litigated) |
| File Marked Found | 17 Dec, 2015 | US6667050 (Litigated) |
| Termination or Final Written Decision | 20 Aug, 2015 | US7704984 (Litigated) |
| Petition Requesting Trial | 03 Feb, 2015 | US7704984 (Litigated) |
| Change in Power of Attorney (May Include Associate POA) Critical | 30 Apr, 2010 | US6667050 (Litigated) |
| Correspondence Address Change Critical | 29 Apr, 2010 | US6667050 (Litigated) |
| Patent Issue Date Used in PTA Calculation Critical | 27 Apr, 2010 | US7704984 (Litigated) |
| Recordation of Patent Grant Mailed Critical | 27 Apr, 2010 | US7704984 (Litigated) |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Lo Minastrin Fe and ongoing litigations to help you estimate the early arrival of Lo Minastrin Fe generic.
Lo Minastrin Fe's Litigations
Lo Minastrin Fe been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Feb 03, 2015, against patent number US7704984. The petitioner Mylan Pharmaceuticals Inc., challenged the validity of this patent, with Warner Chilcott Company, LLC as the respondent. Click below to track the latest information on how companies are challenging Lo Minastrin Fe's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7704984 | February, 2015 |
Terminated-Denied
(20 Aug, 2015) | Warner Chilcott Company, LLC | Mylan Pharmaceuticals Inc. |
US patents provide insights into the exclusivity only within the United States, but Lo Minastrin Fe is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Lo Minastrin Fe's family patents as well as insights into ongoing legal events on those patents.
Lo Minastrin Fe's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Lo Minastrin Fe's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 02, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Lo Minastrin Fe Generic API suppliers:
Ethinyl Estradiol; Norethindrone Acetate is the generic name for the brand Lo Minastrin Fe. 16 different companies have already filed for the generic of Lo Minastrin Fe, with Xiromed having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Lo Minastrin Fe's generic
Alternative Brands for Lo Minastrin Fe
Lo Minastrin Fe which is used for preventing pregnancy., has several other brand drugs in the same treatment category and using the same active ingredient (Ethinyl Estradiol; Norethindrone Acetate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apil |
| |||||||||||
| Bayer Hlthcare |
| |||||||||||
| Evofem Inc |
| |||||||||||
| Organon |
| |||||||||||
| Teva Branded Pharm |
| |||||||||||
| Wyeth Pharms Inc |
| |||||||||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Ethinyl Estradiol; Norethindrone Acetate. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Apil |
| |
| Millicent Pr |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Ethinyl Estradiol; Norethindrone Acetate, Lo Minastrin Fe's active ingredient. Check the complete list of approved generic manufacturers for Lo Minastrin Fe
About Lo Minastrin Fe
Lo Minastrin Fe is a drug owned by Allergan Pharmaceuticals International Ltd. It is used for preventing pregnancy. Lo Minastrin Fe uses Ethinyl Estradiol; Norethindrone Acetate as an active ingredient. Lo Minastrin Fe was launched by Apil in 2013.
Approval Date:
Lo Minastrin Fe was approved by FDA for market use on 24 July, 2013.
Active Ingredient:
Lo Minastrin Fe uses Ethinyl Estradiol; Norethindrone Acetate as the active ingredient. Check out other Drugs and Companies using Ethinyl Estradiol; Norethindrone Acetate ingredient
Treatment:
Lo Minastrin Fe is used for preventing pregnancy.
Dosage:
Lo Minastrin Fe is available in tablet, chewable, tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.01MG,0.01MG,N/A;1MG,N/A,N/A | TABLET, CHEWABLE, TABLET | Discontinued | ORAL |